Latest News
Cadrenal Therapeutics, Inc.
- Cadrenal Therapeutics evaluating strategic options
- Form 4 Cadrenal Therapeutics Inc: Quang X. Pham (Director, 10% Owner, Chairman and CEO) For: 9 October
- Form 4 Cadrenal Therapeutics Inc: Glynn Wilson (Director) For: 9 October
- Cadrenal Therapeutics Director John Raymond Murphy Receives 75,000 Stock Options on October 9, 2026
- Fully vested options go to Cadrenal Therapeutics (CVKD) CEO: 200,000 with a $0.91 exercise price.
- Cadrenal Therapeutics (CVKD) director gets 75,000 options, immediately exercisable at $0.91.
- Cadrenal Therapeutics Retains Tungsten Advisors for Formal Strategic Review
- Cadrenal Therapeutics launches strategic review, hires Tungsten Advisors
- Cadrenal launches strategic review for late-stage cardiology pipeline
- Cadrenal Therapeutics Retains Tungsten Advisors to Lead
- Cadrenal Therapeutics Initiates Board-Approved Strategic Review to Enhance Company Value
- Cadrenal Therapeutics shareholders approve equity plan amendment and warrant issuance
Headlines from the last 30 days, linking to the original publishers. See all market news →